# Temporary Scheduling of Bromazolam and Novel Benzodiazepines > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/ > **Published:** 2026-06-18T12:02:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:24:36-04:00 > **Clinical Summary:** Explore the temporary scheduling of novel benzodiazepines like bromazolam and its clinical and regulatory implications under the Controlled Substances Act. --- โœฆ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. โš’ Policy Watch ย |ย  Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA schedulingcannabis legislation[medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) Clinical Summary The DEA has temporarily placed bromazolam, a novel benzodiazepine analog, into Schedule I of the Controlled Substances Act due to its emerging abuse potential and lack of accepted medical use. This action reflects regulatory response to the proliferation of designer benzodiazepines in illicit drug markets, which often arise as chemically modified alternatives when established controlled substances face restrictions. While bromazolam itself is not cannabis, this scheduling decision exemplifies the regulatory framework clinicians operate within and underscores how the DEA responds to novel psychoactive substances that may be used concurrently with or instead of cannabis by patients seeking anxiolytic effects. Clinicians should be aware that patients may present with use of these emerging designer drugs, which carry unknown safety profiles and potential drug interactions with cannabis and other medications. The temporary scheduling provides a legal enforcement mechanism but does not address underlying patient demand for accessible anxiolytic treatments, a clinical gap that sometimes drives patients toward both cannabis and illicit alternatives. Clinicians should remain vigilant for patient use of novel benzodiazepine analogs and consider evidence-based cannabis or FDA-approved anxiolytic options when managing [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/). Clinical Perspective ๐Ÿ’Š The temporary scheduling of bromazolam as a Schedule I controlled substance reflects ongoing regulatory responses to novel benzodiazepine analogs appearing in illicit drug markets, a trend that complicates clinical toxicology and overdose management. Bromazolam, a designer benzodiazepine with potency comparable to established agents, poses particular risks because it may not be detected by standard urine drug screens and clinical presentation may be indistinguishable from pharmaceutical benzodiazepine intoxication, yet standard benzodiazepine antagonism (flumazenil) remains the appropriate emergency intervention. Clinicians should remain alert to the possibility of novel benzodiazepine exposures in patients presenting with unexplained sedation, respiratory depression, or altered mental status, particularly those with known substance use or exposure to counterfeit medications or illicit drugs. The regulatory action, while necessary for [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan โ†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion โ†’](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [๐• Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+Bromazolam+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F16%2F2026-05064%2Fschedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F16%2F2026-05064%2Fschedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)[๐Ÿฆ… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+Bromazolam+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F16%2F2026-05064%2Fschedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)[๐Ÿ“ท Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[๐Ÿ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[๐Ÿ”” Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-update/) - Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I ๐Ÿ“ฐ Source: [https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Schedules of Controlled Substances: Placement of Diphenidine in Schedule I Review the regulatory placement of Diphenidine in Schedule I and its implications for clinical practice and drug enforcement. Read More [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Explore the temporary scheduling of 2-Fluorodeschloroketamine and its clinical and regulatory significance. [Learn More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Understand the scheduling of CUMYL-PEGACLONE in Schedule I and its impact on clinical toxicology and drug policy. [Discover More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR ยง 164.514(b)) and criteria for secondary research exemption under 45 CFR ยง 46.104(d)(4).